RxDoctor Payments Data

Justin Moellinger, MD

Surgery · Bessemer, ALNPI 1134290984

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.8% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 46 manufacturers reported payments, led by AbbVie at 36.3% of the total. Reporting peaked in 2019 at $2,521 and has fallen 64.8% since, to $887 in 2025.

$10,331in general payments, 2019–2025

Across 260 payments — averaging $39.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Integra Lifesciences Corporation$770
  • Smith+Nephew$637
  • C. R. Bard, Inc. & Subsidiaries$629
  • Innovation Technologies Inc$544
  • Johnson & Johnson$447
  • plus $4K from 40 others

What the payments were for

  • Travel & lodging$6396%
  • Food & beverage$9,69294%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,331 in reported general payments places this provider in the 85th percentile of 382 surgery providers in Alabama.

See all surgery providers in Alabama

Medicare billing

Part B allowed, 2024
$81,674
Medicare patients
157
Services billed
707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DalvanceDalbavancin Hcl27$144,247
Daptomycin66$133,123
Meropenem83$17,411
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav52$989
Sodium Chloride0.9 % Sodium Chloride74$756
Ciprofloxacin Hcl19$598
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen102$561
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen88$498
Levofloxacin54$460
Ondansetron OdtOndansetron59$443
Fluconazole18$367
Doxycycline Monohydrate13$349
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim28$263
Clindamycin Hcl14$222
Dextrose In WaterDextrose 5 % In Water25$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieDalvance$3,751$144,24727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 382 surgery providers in Alabama.

Other surgery in Bessemer

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →